Secondary endpoints of a randomized, placebo-Controlled Pilot Study to evaluate the safety of lyophilized PRIM-DJ2727 in Parkinson’s disease
Objective: To evaluate the impact of fecal microbiome transplant (FMT) on disease progression as a secondary outcome of a safety study using PRIM-DJ2727 in Parkinson's…The gut microbiome in Parkinson’s disease: longitudinal insights into disease progression and the use of device-assisted therapies.
Objective: We investigated the temporal stability of gut microbiome (GM) profiles from Parkinson’s disease (PD) patients initiating device-assisted therapies (DAT) and in a separate cohort…Gut microbiota and nutritional profiles of Parkinson’s disease patients.
Objective: We investigated the gut microbiome (GM) composition in association with various clinical features and nutritional data in a large cross-sectional Australian Parkinson’s disease (PD)…Constipation in Parkinson’s disease: Clinical and Neurosonographic Study
Objective: We aimed to study the possible impact of constipation on motor, non-motor, depressive symptoms, cognitive functions and neurosonographic findings in idiopathic Parkinson's disease (PD)…Deposition of phosphorylated α-synuclein in the muscularis externa of the gastrointestinal tract in patients with prodromal Parkinson’s disease
Objective: In the present study, we investigated Lewy pathology in the enteric nervous system (ENS) of seven Parkinson’s disease (PD) patients who underwent a gastrectomy,…A study of gut microbiota dynamics in Parkinsonian mice
Objective: To examine gut microbiota in the M83 mouse model of PD. Background: Parkinson’s disease (PD) is a chronic neurodegenerative disease characterized by motor and…Does constipation predict cognitive impairment and dementia in de novo Parkinson’s disease patients? A multi-cohort longitudinal data analysis
Objective: To investigate if constipation predicts the development of cognitive impairment (CI) and dementia in de novo Parkinson’s disease (PD). Background: Constipation is one of…Temporal characterization of motor, gastrointestinal, and behavioral symptoms in a SNCA A53T transgenic mouse model of Parkinson’s disease
Objective: While multiple animal models of Parkinson’s disease (PD) have been developed with varying applicability to different aspects of the disorder, no single model effectively…Association between essential tremor, constipation, and the risk of developing Parkinson’s disease
Objective: To evaluate the association between constipation and the risk of Parkinson’s disease (PD) in patients with a prior history of essential tremor (ET). Background:…Intestinal Methanogen Overgrowth (IMO) More Prevalent than SIBO in Parkinson’s disease with Constipation: Preliminary Results
Objective: Our aim is to quantify the prevalence of small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) in PD subjects with constipation compared…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 9
- Next Page »